Abstract. CYP3A4 is involved in tuberculosis (TB) and human immunodeficiency virus (HIV) drug metabolism. Transcriptional activation by rifampicin involves the CYP3A4 gene 5'-upstream region. Consequently, variation may interfere with transcription and enzymatic activity and even drug response. However, genetic polymorphisms and distribution of CYP3A4 allelic frequencies in individuals from Rio de Janeiro remain unknown. The aim of this study was to conduct research into sequencing the CYP3A4 5'-upstream region in Brazilian patients with and without HIV. This follow-up study involved 106 individuals undergoing treatment for TB and/ or HIV. The CYP3A4 5'-upstream region was analyzed using PCR, sequencing and clinical data. Male patients revealed a higher HIV frequency (p=0.021). The TB forms observed were pulmonary (48.1%), extrapulmonary (22.64%) and disseminated (27.36%). Lymph node form was the most frequent (70.83%) extrapulmonary form of TB. The only single nucleotide polymorphism detected in the population was c.-392A>G. Genotypes observed were CYP3A4*1A/CYP3A4*1A (45.3%), CYP3A4*1A/CYP3A4*1B (40.6%) and CYP3A4*1B/ CYP3A4*1B (14.2%), revealing a different distribution with extrapulmonary TB cases (17.6% CYP3A4*1A/CYP3A4*1B and 23.5% CYP3A4*1B/CYP3A4*1B). The CYP3A4*1A allele was found to be associated with tobacco use. The CYP3A4*1B mutant allele occurred in 34% of patients. This study revealed that the CYP3A4 5'-upstream regulatory region was highly conserved with the exception of the -392 position. Genotype association with tobacco suggests that CYP3A4 may participate in tobacco metabolism. Genotype distribution inversion in extrapulmonary TB cases suggests that CYP3A4 may be involved in TB prognosis.
Introduction
The CYP3A4 enzyme concurs for phase I drug metabolism in humans with specificity for several substrates, and is responsible for the oxidation of many therapeutic drugs (1) . Rifampicin, an antibiotic commonly used for tuberculosis (TB) treatment (2, 3) , protease inhibitors and non-nucleoside reverse transcriptase inhibitors used for human immunodeficiency virus (HIV) therapy (4, 5) , and many medicines from the anti-inflammatory and antibiotic classes (2-6) have been described as inhibitors or inductors of CYP3A gene expression (3, (6) (7) (8) .
CYP3A expression is increased by the transcriptional activation intermediated by the pregnane X receptor (PXR), a nuclear receptor that is the principal activator of CYP3A transcription and which plays a central role in regulating many genes involved in drug metabolism and elimination. In this way, PXR responsive elements on DNA have been considered significant in predicting and preventing drug interactions, metabolism and disposition (2, 9) .
Considering the involvement of CYP3A4 enzymes in the metabolism of steroids, fatty acids, xenobiotics and the nicotinamide adenine dinucleotide phosphate (NADP)-dependent electron transport pathway (2,7,10,11), we could expect the CYP3A4 metabolic pathway to be directly or indirectly involved in response to infections. Indirect involvement appears to mobilize transcriptional activation factors.
During CYP3A4 transcriptional activation by xenobiotics such as rifampicin, the PXR binds to and is activated by the drug (12) . The PXR drug complex forms a heterodimer with the retinoid X receptor (RXR) and binds to the PXR response elements on the CYP3A4 gene promoter (3) . Therefore, polymorphisms in this region may interfere with transcription or enzyme activity.
The nuclear vitamin D receptor (VDR) is the receptor with the highest identity sequence to PXR (9) . There is evidence for the essential role of VDR in mediating the vitamin D actions. The receptor binds to the hormonal metabolite of vitamin D 1,25-dihydroxyvitamin D3 [1,25(OH) 2 
D3]. Similar
Unique CYP3A4 genetic variant in Brazilian tuberculosis patients with/without HIV to PXR, the 1,25(OH) 2 D3-VDR complex interacts with RXR, generating a heterodimer. Following interaction, the resultant complex binds to the dihydroxyvitamin D(3) receptor (DR3) hormone responsive element on DNA (13) . It induces calcium/ phosphate translocation in tissues such as bone (resulting in normal bone mineralization and remodeling), intestine and kidney (13) . Moreover, there are apparent vitamin D bioactivities in other targets, such as cells of the neural, endocrine and immune systems. In this way, 1,25(OH) 2 D3 acts as a general suppressor, particularly of T-helper cells (13) . Concerning this, VDR and tumor necrosis factor-α (TNF-α) genes are crucial in the intracellular killing of Mycobacteria tuberculosis (14) . In addition, genetic studies have revealed an association between genetic variants of the natural resistance-associated macrophage protein (NRAMP1) and VDR genes and smearpositive pulmonary TB (15) . Evidence regarding the 1,25(OH) 2 D3-VDR complex has shown that after binding to the RXR heterodimer, this complex interacts with the PXR response elements on the CYP3A4 gene promoter (12, 16) . It suggests that CYP3A4 enzymes or signaling involving CYP3A4 may be associated with susceptibility to the development of pulmonary TB.
There is evidence of CYP3A4 expression in the prostate, breast, colon, small intestine and liver, in which these enzymes amount to 30% of the total CYP protein content (8, (17) (18) (19) (20) . This may be a result of the significant role of CYP3A4 in the oxidation of testosterone and estrogen, as suggested in studies researching the mechanisms involved in breast cancer (17, 21) and androgen-mediated prostate carcinogenesis (16) .
The CYP3A4 gene is located on chromosome 7q21.3-q22.1 and consists of 27.592 base pairs and 13 exons. Its 5'-flanking region (5'-untranslated region or UTR) includes a basal transcription element at the -35 to -50 promoter region, an AP-3 binding site, an estrogen response element, a glucocorticoid response element, a hepatocyte nuclear factor-4 (HNF4) element, two HNF-5 elements and a protein p53 binding motif (22, 23) .
The occurrence of genetic variants of CYP3A4 was noted following the detection of ethnic variation in CYP3A metabolism in comparative studies of triazolam pharmacokinetics and pharmacodynamics between Caucasians and Southern Asians (24) . The association with ethnicity was also found in studies analyzing 6β-hydroxycortisol:cortisol conversion ratios (21) .
The first molecular approach in the study of CYP3A4 used conformation sensitive gel electrophoresis (CSGE) of the PCR product to analyze Caucasian males with prostate cancer. The genetic variant CYP3A4-V (CYP3A4*1B) was identified, which presented the alteration c.-392A>G on the CYP3A4 promoter with a frequency ≥0.01. CYP3A4*1B was associated with a higher tumor lymph node metastasis stage and Gleason grade. The authors concluded that a single base change or single nucleotide polymorphism (SNP) in the 5'-flanking region of the CYP3A4 gene may influence prostate carcinogenesis (16) . Following this, the CYP3A4*1B allele was also detected in other studies analyzing genetic polymorphisms in the 5'-upstream regulatory region and hepatic expression of CYP3A4 (25) . Sequencing analysis provided additional evidence of this variant in Caucasian, African-American and Chinese individuals (26) .
A posterior haplotype approach supported the association of the CYP3A4*1B allele with prostate cancer in CYP3A4*1B and CYP3A5*1, as well as CYP3A4*1B and CYP3A5*3 haplotypes (27) .
CYP3A4*1B has also been associated with the development of breast cancer in females with early-onset menarche from the US (African-American, Hispanic and Caucasian) (28) . Conversely, a case-control study found no association between the functional implication of this polymorphism and breast or ovarian cancer in Australian Caucasian women (29) .
Regarding the involvement of CYP3A4 in the metabolism of certain TB and HIV treatment drugs, the occurrence of CYP3A4 gene variants, mainly those affecting regulatory regions, interferes in gene transcription, enzyme activity and other regulatory events. Therefore, these variants may influence drug metabolism and cause many adverse effects. Furthermore, polymorphisms in the CYP3A4 5'-upstream region may interfere indirectly in the response to infection, since this region interacts with the VDR-containing complex associated with TB infection. Since CYP3A4 polymorphisms and allelic frequencies in individuals from Rio de Janeiro remain unknown, effort is required to provide knowledge of this issue. In this way, the aim of this study was to research the CYP3A4 5'-upstream region in Brazilian TB patients co-infected or not with HIV, and to investigate whether genotypes could be involved in the evolution of the TB infection. The main variables were gender, HIV status, tobacco use, skin color classification and TB clinical form. HIV status was defined as negative or positive depending on the serology result in the patient's medical chart. Tobacco use was classified as positive (smoker) when patients answered yes to the questionnaire about smoking in the medical records. The diagnosis of TB was based on the recommendations of the Brazilian Ministry of Health described in the National Program for Tuberculosis Control (30) .
Materials and methods

Subjects
TB clinical presentation (clinical form) was defined as pulmonary, extrapulmonary or disseminated form following the information in the patient's medical chart. Pulmonary TB was diagnosed through medical evaluation for TB in the lungs, which included medical history, physical examination, chest X-ray and microbiological examination (by identifying the Mycobacterium tuberculosis in a sputum sample). Extrapulmonary TB was diagnosed in patients with TB affecting areas other than the lungs. To obtain information on infection evolution, the subcategories of extrapulmonary forms were analyzed. These cases were described depending on the location of affected organs and/or tissue. Disseminated TB was diagnosed as a TB infection that had spread from the lungs to other parts of the body through the blood or lymph system.
DNA sample and extraction. Peripheral blood samples (5 ml) collected from each patient were stored at -20˚C in sterile EDTA vacutainer tubes until DNA extraction. Genomic DNA extraction was performed using the QIAamp DNA Blood Mini kit (Qiagen, Santa Clara, CA, USA) following the manufacturer's instructions.
CYP3A4 5'-upstream amplification. CYP3A4 5'-upstream region amplification was obtained by polymerase chain reaction (PCR) resulting in a 661-bp product, using primers designed based on the Ensembl Gene Report for ENSG00000160868 (CYP3A4 gene, CYP3A4-202 transcript, exon info ENST00000336411) (31) with the NCBI primer tool (32). The forward primer was CYP3A4F (5'-TGAGGAGCTCACCTCTGTTC-3') and the reverse primer was CYP3A4R (5'-GAGCAACACAGAGCTGAAAGG-3'); these were designed for annealing specifically at position -698 to -679 (CYP3A4F) and -58 to -38 (CYP3A4R) in the CYP3A4 gene. PCR was performed in a 50-µl mixture containing genomic DNA, 2.5 units of AmpliTaq DNA polymerase (Invitrogen), 20 pmol of each primer, 0.2 mM of each dNTP (Invitrogen), 1.5 mM MgCl 2 and 1X PCR buffer (Invitrogen). Following initial denaturation at 95˚C for 5 min, 35 cycles of 94˚C for 1 min, 59.5˚C for 1 min and 72˚C for 2 min were performed. Next, a final elongation at 72˚C for 10 min and a hold cycle at 4˚C were performed. Following gel electrophoresis of a small quantity of each sample to confirm amplification, PCR product purification using the Wizard kit (Promega) was performed, following the quantitative analysis by gel electrophoresis using low mass DNA ladder and DNA sequencing using 1 pmol of each primer. CYP3A4 5'-upstream genotype analysis was performed by analysis of electropherograms using sequences obtained with reverse and forward primers, simultaneously, for each sample. The reaction products were analyzed on the ABI Prism ® 3730 DNA Analyser at 'Plataforma Genômica-Sequenciamento de DNA-RPT01A-PDTIS/FIOCRUZ'.
CYP3A4 5'-upstream genotype determination.
The description of sequence variations was based on GenBank sequence AF280107 of the CYP3A4 gene (32) and the Ensembl Gene Report for ENSG00000160868 (CYP3A4 gene, complete sequence CYP3A4-001 transcript, exon info transcript ID ENST00000336411; 13 exons; transcript length 2.153 bp; translation length 503 residues) (31). The sequences were edited and assigned using Sequencer 4.1.4 software. The GenBank sequence AF280107 (32) was used as a reference for comparisons of DNA using Sequencer 4.1.4. The region analyzed was -698 to -38 of the CYP3A4 gene, which corresponds to positions 61340 to 62000 in AF28017 Nucleotide Loccus in GenBank and 99382402 to 99381742 chromosome bp -system used to register variations in Ensembl (Line Numbering Relative to Coordinate Systems).
Positions of nucleotides are given as distances in base pairs from the first ATG (methionine translational start signal), in which A is the nucleotide +1 and its adjacent 3' nucleotide is -1. The A base of CYP3A4's first ATG is found at position number 62037 in the GenBank entry identified by accession number AF280107. Guidelines for naming variants were NCBI and Ensembl patterns, which follow the recommendations of the human nomenclature committee (33). The search for variants in the 5'-upstream regulatory region of CYP3A4 included positions previously identified with DNA sequence variants described previously, revised by Keshava et al (34) and available in the Ensembl SNP register of December 6, 2009 .
To allow greater convenience and speed in the comparative analysis of the sequences using Sequencer, the positions of variants in the amplicon (position in amplicon) were determined considering the first base of the forward primer (5' end) as base 1 and the last base of the forward primer as base 661. After that, in results, the conventional position based on GenBank and Ensembl was shown.
Statistical analysis. Proportions (%) for the categorical data of gender, skin color, smoking, TB clinical form, TB extrapulmonary forms, CYP3A4 alleles and genotype distribution were used to describe characteristics in the studied population. Data analysis involved comparisons of proportions and analysis of the association of genotypes with the clinical characteristics. The Pearson Chi-square or Fisher's exact tests were used for categorical variables in the contingency tables analysis. A p-value of p<0.05 or 5% was considered significant. All analyses were carried out using the R software (package Epicalc). 
Results
Patient characteristics. The demographic and clinical characteristics of the patients concerning gender are described in Table I . The majority of patients were male (67.9%), who showed the highest frequency of HIV infection (47.2%, p=0.021). Regarding patient skin color, the majority (53.8%) was classified as non-white (black or brown skin color). The skin color distribution was homogenous with relation to gender ( Table I) . As shown in Table II , TB clinical forms observed were pulmonary (48.1%), extrapulmonary (22.6%) and disseminated (27.3%). Among extrapulmonary cases, the majority was lymph node form (70.83%) and other forms were much less frequent (Table II) .
Regarding tobacco use, it was observed that 30.2% of patients were tobacco users against 65.1% that were not (Table III) . Tobacco use was more frequent in males (81.25% vs. 18.75% in females), but without significant association. Considering TB clinical form, tobacco use was more frequent in pulmonary TB cases, followed by disseminated and extrapulmonary forms, respectively (Table III) .
CYP3A4 sequence analysis. The primers designed allowed coverage of the entire regulatory region and upstream region and beyond that, permitting the description of nearly 600 bp for each patient. Comparative analysis of the DNA sequence of patients and comparisons between them and the reference sequence (GenBank AF280107) revealed that the analyzed region in all 106 studied individuals was very similar to the reference sequence. Performing a direct search focusing on the 20 SNP regions registered in the Ensembl genomic database, it was observed that 19 of the 20 analyzed positions revealed the same bases corresponding to the wild reference sequence.
The genotypes identified in the patients are shown in Table IV , which shows the bases in Brazilian samples corresponding to each one of the SNPs described in the Ensembl database. By searching the literature and the Ensembl SNP databank, it was verified that to date 20 positions have been identified with SNP in the CYP3A4 studied region. The percentage of homozygosity was 100% for almost all positions with the exception of position c.-392, which carried CYP3A4*1A alleles (characterized for the 'a' base) or CYP3A4*1B (characterized for the 'g' base). The distribution of genotypes at this polymorphic region is shown in Table IV , and the classification of alleles and genotypes is shown in Table VI . A significant correlation was found between CYP3A4*1A and tobacco consumption (p=0.0145). The 13.3% of consumers registered for GG patients (CYP3A4*1B) increased to 25.6% in individuals carrying only one copy of the CYP3A4*1A (AG) allele and reached 39.6% among the AA homozygous individuals. With regard to TB clinical form, the disseminated form AG and AA genotypes revealed similar frequencies (44.8 and 41.4%, respectively), while the GG genotype was rare (13.8%). Among TB extrapulmonary forms, AA genotype was the most frequent (54.2%), followed by AG (29.2%) and GG (16.7%) genotypes. Among TB pulmonary form, AG and AA genotypes were the most frequent (45.1 and 41.2%, respectively), while the GG genotype was less frequent (13.7%). The same was observed among TB extrapulmonary forms, in which lymph node forms were the most frequent (70.8%); the AA genotype being the most frequent (58.8%), followed by the GG and AG genotypes identified in 23.5 and 17.6% of patients, respectively. With regard to HIV status and skin color, a similar distribution of the various genotypes was observed.
Discussion
Patient characteristics. T he high percentage of TB-HIV-positive serology among patients was a predictable result due to the fact that IPEC is a reference center of HIV and TB-HIV. Additionally, the frequency of positive serology for HIV being significantly higher among males (p=0.021) is in correlation with the HIV prevalence in males registered in Brazil: 22 per 100,000 against 13.9 per 100,000 in females in 2007 (35).
Regarding the differential allelic expression of CYP3A4 associated with many xenobiotics (36) , and the previous evidence indicating that smoking is causatively associated with active TB (37, 38) , alterations in the CYP3A4 regulatory region may influence the activity or expression of the enzyme, and could be related to variation in drug interaction, including tobacco compounds. In this study, the tobacco consumption frequency among patients was twice (32%) as high as that previously described in the Brazilian population; approximately 16%, ranging from 9.5% in Salvador to 21.2% in Porto Alegre and Rio Branco cities (39) . Additionally, when each TB clinical form was analyzed separately, 15.62% of the patients with the extrapulmonary form of TB were smokers. This number increased to 25% among disseminated cases and to 59.4% among patients with pulmonary TB. This indicates that among pulmonary TB patients, the percentage of smokers was 3.7 times higher than that observed in the Brazilian population. In this way, besides the absence of a significant association between smoking and TB clinical form or extrapulmonary TB, it was verified that smokers were the majority among patients with pulmonary TB. These results suggest that smoking may be related to pulmonary TB, which correlates with previous data linking smoking and active TB (37, 38) . Additional studies using a case-control approach may clarify this issue.
CYP3A4 sequence analysis. The screening of SNPs in the CYP3A4 upstream region in Brazilian patients based on a Human Genome Epidemiology Review (34) and the Ensembl databank revealed that almost all SNPs were absent in the studied population. These SNPs were identified in Asian individuals originating from Japanese and Chinese populations (34) . In this study, the SNP c.-392A>G was the only sequence variation identified in Brazilian patients undergoing TB treatment at the IPEC Hospital in Rio de Janeiro. This SNP (c.-392A>G) corresponds to CYP3A4-V previously detected in a study of Caucasian volunteers by Rebbeck et al (16) .
Westlind et al obtained similar results when analyzing the most proximal 5'-upstream region from +10 to c.-490 bp, which contains the CYP3A4 promoter, in 39 individuals, through the sequencing of nested PCR amplicons. It was observed that the only variation was the A>G mutation at position c.-290 corresponding to CYP3A4-V (25) . Our results support those of previous studies indicating that this CYP3A4 gene is highly conserved, and concur with previous data demonstrating that the upstream region is highly preserved (25, 40) . Moreover, the variation of CYP3A4 among populations reinforces the necessity of studying this gene in Brazilian individuals.
Also termed CYP3A4*1B, CYP3A4-V represents the most common polymorphism observed in the promoter region in the nifedipine-specific response element (NFSE) with a change at position c.-392 from A to G (agggcaagag to agggcaggag) (16) . However, this variant is presented as a G to A mutation in the Ensembl databank (99382096:G/A).
CYP3A4 and clinical characteristics. CYP3A4-V frequency was approached mainly in prostate cancer and leukemia studies (16, 40, 41) . Initially, researchers focused on searching for an association between genotypes and cancer development. Then, a novel approach was described, searching for the association of genotypes with cancer prognosis, reflected by a correlation between CYP3A4-V and the high aggressiveness of prostate cancer (42) .
In this study, no association was found between a specific CYP3A4 genotype and the development of a particular TB clinical form. However, in the pulmonary and disseminated forms of TB, it was observed that the AG genotype (wild-type or CYP3A4-V) was slightly more frequent than the AA genotype. Furthermore, among TB extrapulmonary forms, the AA genotype (wild-type) was the most frequent, particularly when focusing on the most commonly observed lymph node forms. These results suggest that there is a possibility of finding an association between the CYP3A4 genotypes in the upstream regulatory region and TB clinical form. Case-control studies comparing genotype distribution between TB and non-TB patients may provide useful information to clarify this. The majority of clinical studies involving CYP3A4 have used the frequency of CYP3A4-V as a tool to analyze associations with cancers that are more common in a specific ethnic group. An investigation comparing ethnicities performed by Walker et al detected that CYP3A4-V was more frequent in African Americans, being observed in 53% of cases. In Caucasians, it was presented in only 9%, whereas in Taiwanese it was not observed (0%). Conversely, the wild-type allele (CYP3A4*1A, agggcaagag) was the most frequent form in Caucasians and the Taiwanese (41). Zeigler-Johnson et al found similar results in studies focusing on prostate carcinogenesis. Analyzing genotypes at the SRD5A2 and CYP3A4 loci, the authors detected the highest frequency of CYP3A4-V in Ghanaians and African Americans (>50%), while in Caucasians it was less than 10% and in Asians it was non-existent (40) .
CYP3A4*1B (as CYP3A4-V) was previously studied in Brazilian patients by Fiegenbaum et al investigating the role of ABCB1, CYP3A4 and CYP3A5 genes in simvastatin treatment in patients living in Rio Grande do Sul (43) . The same group performed a cross-sectional study investigating possible associations between polymorphisms in genes related to estrogen biosynthesis and estrogen catabolism. In both studies, SNP CYP3A4-V was the only CYP3A4 variant searched for in the upstream region (44) . Since these investigations used PCR and restriction mapping analysis as a molecular biology approach, these punctual studies assumed CYP3A4-V to be the only possible variation without a previous SNP screening.
In this regard, the present study provides additional data, providing the largest vision of the CYP3A4 upstream regulatory region, obtained through the first attempt at sequencing performed on Brazilian individuals. Moreover, our results indicate the possibility of using direct CYP3A4-V focus in Brazilian individuals as PCR and RFLP, although other studies with populations originating in other Brazilian states and with different ethnicity are required for a secure analysis. Furthermore, it is also necessary to remember that these previous studies of CYP3A4 in Brazilian individuals have analyzed those of European descent, while this study focused on individuals living in a southeastern state with different ethnicity. Brazil presents a large miscegenation of native American Indians, European Caucasians and African blacks that originate from various countries. Due to Brazil's large size, topographic diversity and colonization history, different regions show singular prevalence of ancestry with reflects on the population subtypes (45) . This justifies the need for studies focusing on different regions of Brazil and different population subtypes.
The haplotype analysis in this study revealed that CYP3A4*1B was observed in 34% of patients and CYP3A4*1A in 66%. Thus, the CYP3A4*1B frequency was much lower than that observed in African Americans (40, 41) and Ghanaians (40) , while CYP3A4*1A was the highest, although lower than the 90-100% described in Caucasians and Asians, respectively (40) . These results demonstrate that, in Brazilians, CYP3A4*1B and CYP3A4*1A have a peculiar distribution. Although many studies have connected CYP3A4 genotypes with ethnicity (36, 40, 41, (46) (47) (48) , in this study the genotype distribution revealed no correlation with patient skin color. Besides this, it was observed that the GG genotype was twice as common in non-white people (66.7%). Regarding the AG genotype, most carriers were non-white, while with the AA genotype most were white.
Besides the miscegenation in the population analyzed in this study, which causes difficulty when making comparisons, a similar tendency was also observed in the haplotype distribution with relation to skin color in investigations performed by Schirmer et al. They observed that CYP3A4*1A exhibited a high haplotype homozygosity (AA haplotypes) in European Caucasians, while it was low in African Americans. In other words, individuals of African descent demonstrated a high level of homozygosity to CYP3A4*1B (GG haplotypes) and AG heterozygous haplotypes. Since CYP3A4 is involved in vitamin D metabolism and carriers of CYP3A4*1B allelles exhibit higher expression of this enzyme, it is hypothesized that the deficiency in Vitamin D due to decreased ultraviolet intensity could be a selecting factor responsible for the apparent elimination of CYP3A4*1B alleles, in non-African populations (46) .
Considering that the active form of vitamin D (1,25(OH) 2 D3) has been shown by in vitro studies to inhibit the growth of Mycobacterium tuberculosis through activating monocytes and cell-mediated immunity, it was suggested that vitamin D status may be associated with the risk of TB development (49) . It was reinforced in a recent case-control study involving 166 Vietnamese TB patients confirming the association between vitamin D deficiency and TB in man (p= 0.01) (50) . Previous investigations have found that 25-hydroxycholecalciferol (serum vitamin D) deficiency or absence was associated with active TB and an association was detected between the combination of VDR genotypes and 25-hydroxycholecalciferol deficiencies with TB development (51) . In this study, involving 45.3% of patients carrying AA and 40.6% of patients carrying AG genotypes, a total of 85.9%, it would be expected that most individuals demonstrated a functional vitamin D metabolism and a satisfactory immune response to TB. In this way, other clinical and genetic studies concerning VDR and the CYP3A4 upstream region together may clarify the possibility of using these genetic regions for TB prognosis and prediction.
Clinical research (47) and in vitro functional analysis (25,48) generated controversial results concerning the affects of carrying CYP3A4-V. Studies of patients with the wild-type genotype (CYP3A*1A or CYP3A4-W) found that these individuals may be at an increased risk of treatmentrelated leukemia. The authors suggested that it may be a result of epipodophyllotoxin and other chemotherapeutic agent metabolism by CYP3A4. In this way, CYP3A4-V may damage the metabolism of anticancer drugs, reducing the production of potentially DNA-damaging reactive intermediates (47) . Beyond the suggested roles in cancer response and TB immune response, the CYP3A4 gene may be explored in approaches for the prediction of therapy response in AIDS and TB, since CYP3A4 demonstrates a role in the metabolism of anti-HIV and anti-TB drugs (2) (3) (4) (5) (6) (7) (8) .
Besides analysis using a human liver microsome system, which found no apparent correlation between CYP3A4 genotypes and nifedipine oxidation activity (25) , and in vitro tests using a liver, which revealed that CYP3A4*1B has only a moderate effect on mRNA and protein construction (46) , there is evidence linking the CYP3A4 polymorphism and CYP3A4 mRNA production and protein expression through clinical approaches. Transcriptional and genotyping analysis using liver samples from 18 Caucasian donors found an association between allelic constitution and CYP3A4 mRNA levels. Due to this, the authors suggested that CYP3A4 alleles or haplotypes lead to the total hepatic CYP3A4 mRNA, producing a different enzymatic level that may have an effect on the metabolic capability, as indirectly measured through testosterone 6β-hydroxylation (36) .
Therefore, comparative analysis combining clinical and social characteristics of TB patients with CYP3A4 genotypes may provide crucial information on the possibility of involvement of the CYP3A4 polymorphism in disease prognosis and drug response in patients. Furthermore, considering the association between VDR variants and pulmonary TB infection previously described (14) , given that VDR-containing complex binds to the CYP3A4 5'-upstream region, it may be expected that a particular polymorphism in the CYP3A4 regulatory region would be associated with pulmonary TB.
In this study, a differential distribution between genotypes and TB infection was found focusing on the extrapulmonary TB forms. The lymph node cases were the most frequent (70.83%), of which 58.8% were diagnosed in individuals with the AA genotype. This result concurs with the highest AA frequencies, but the percentage of the other genotypes shows an inverse distribution; GG genotype (23.5%) being more frequent than AG (17.6%). Besides the absence of association, in these cases the inversion in genotype distribution reinforces the possibility that CYP3A4 could be involved in TB prognosis. Regarding extrapulmonary TB, cases of absence of the rarest forms among genotypes impaired carry out association tests, as observed in the larynx TB form in AA patients, oropharyngeal TB for AG patients and skin, laryngeal, oropharyngeal and ophthalmic TB for GG genotypes. In this way, investigations over longer periods with an augmented population and case-control studies involving non-TB patients would provide additional information on the participation of CYP3A4 in response to the TB infection. The possibility of CYP3A4 involvement in patient response to diseases has been previously described with regard to cancer prognosis in many regions around the world (16, 17, 21, 28, 47) , and more recently for TB infection (14) .
To conclude, this study represents the first attempt made to analyze the CYP3A4 upstream region by sequencing in Brazilians with mixed-race ancestry. The similarity of CYP3A4 among patients and also the comparison of CYP3A4 Brazilian characteristics to the reference sequence in GeneBank concur with previous reports indicating that the upstream region of this gene is highly conserved. Furthermore, the association between CYP3A4 genotypes and tobacco use suggests that CYP3A4 enzymes may be involved in tobacco compound metabolism. Considering that tobacco is involved in TB susceptibility, it reinforces the necessity of additional studies aiming to understand this association in a physiological and clinical context. Moreover, further longitudinal investigations monitoring extrapulmonary TB could help to clarify the involvement of CYP3A4 genotypes in TB prognosis.
